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The major immunogen of foot-and-mouth disease virus (PMDV) is located between amino acids 141-160 
of the capsid protein VPl. Synthetic peptides corresponding tothe major immunogenic region give good 
neutralising antibody responses and protection in guinea pigs. To define more precisely the immunogenic 
site of the virus, we have examined serological differences between subtypes of the A serotype using 
synthetic peptides covering the 141-160 region. We show that these synthetic peptides carry determinants 
which mimic the subtype specificity of the virus. The correlation between these results and predictive 
structural models, based on the amino acid sequence, is discussed. 




Foot-and-mouth disease, a highly contagious 
disease of cloven-hooved animals, is of con- 
siderable economic importance. The causative 
agent is a picornavirus having a single-stranded 
positive sense RNA genome of about 8000 
nucleotides [ 11. Foot-and-mouth disease virus 
(FMDV) occurs as 7 distinct serotypes and_ infec- 
tion with one serotype does not confer immunity 
against any of the others. Within each serotype 
further antigenic differences occur and at least 60 
subtypes of the 7 serotypes have been identified. 
These differences are frequently great enough to 
reduce considerably the degree of cross-protection 
conferred by one subtype against another within 
the same serotype [2]. This poses a major problem 
in vaccination programmes. It is therefore of con- 
siderable importance to define precisely the nature 
of the major immunogenic site, so that structural 
features which determine serotype and subtype 
specificity may be better understood. 
Nomenciat~re; Numbering of the amino acids of VP1 is 
normal&d to that of serotype 0, sub-type 1 (Kauf- 
beuren) 171 because of frequent deletions and insertions 
of amino acids in other virus strains 
The major immunogenic region is located on the 
viral capsid protein, VP1 [3] and, from the use of 
defined chemical and enzymatic fragments of this 
protein 141, it has been predicted that amino acid 
sequences 146-154 and 200-213 contain im- 
munogenic sites. The advent of recombinant DNA 
technology has allowed the sequencing of these 
regions in several serotypes of the virus [5-71. The 
region 141-160 has been shown to be highly 
variable and hydrophilic in character, suggesting 
that it is a major antigenic site. This has been fur- 
ther supported by the observations that synthetic 
peptides corresponding to this region give good 
neutralising antibody responses and protection 
from virus challenge in guinea pigs [8,9]. Synthetic 
peptides corresponding to region 200-213 also 
elicit neuralizing antibody, although at a much 
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lower level 181. This work describes an investiga- 
tion into the nature of the antigenic determinants 
located in the 141-160 region. 
2. MATERIALS AND METHODS 
2.1. Vimses 
Two viruses belonging to subtypes 10 and 12 of 
the A subtype were used, namely strain 61 and 
strain 119. These are referred to as A10 and A12, 
respectively. 
2.2. ~e~ra~ion of antisera 
Guinea pigs were injected with: (a) virus 
harvests, grown in baby hamster kidney cells, after 
inactivating them with 0.05% acetylethyleneimine 
at 37°C for 6 h; or (b) synthetic peptides covalent- 
ly linked to keyhole limpet haemocyanin (KLH). 
In each instance the preparations were first mixed 
with an equal volume of Al(OH)s gel. Serum 
samples were obtained from blood taken 21 days 
after injection. Antisera were also produced in rab- 
bits by multiple injections of the KLH-coupled 
peptides according to the schedule described IS]. 
Ten-fold dilutions of the two viruses were mixed 
with an equal volume of normal serum or anti- 
serum dilution and 0.03 ml of the mixtures in- 
jected into groups of 7-day-old mice. The dif- 
ference between. the titres were taken as the 
neutralising activity of 0.015 ml of the antiserum 
dilution. 
2.4. DNA sequencing 
Primer extension experiments were performed 
basically as in [lo] using a synthetic DNA primer 
kindly supplied by Dr M.J. Gait (Laboratory of 
Molecular Biology, MRC, Cambridge). Hybridisa- 
tions were carried out using 20pg FMDV-RNA 
and a S-fold molar excess of radio-labelled primer. 
After the synthesis of cDNA using reverse 
transcriptase, standard sequencing reactions were 
performed [13]. 
2.5. Peptide synthesis 
All peptide syntheses and coupling reactions 
were as in [8]. Essentially peptides were synthesised 
by a solid-phase method and coupled to a protein 
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carrier (KLH) through a cysteine residue at the C- 
terminus of the peptide. 
3. RESULTS AND DISCUSSION 
In previous work, the serotype specificity of the 
antibodies produced in rabbits by peptides spann- 
ing regions 141-160 and 200-213 from serotype 0 
subtype 1, was found to be similar to those elicited 
by injection of whole virus [8]. This infers that 
both peptides carry antigenic determinants involv- 
ed in serotype specificity. To examine those deter- 
minants involved in subtype specificity, we per- 
formed similar experiments using synthetic pep- 
tides corres~nding to two virus subtypes from 
serotype A. We initially checked the amino acid se- 
quence of the viruses being used in this study by a 
rapid sequencing method [&lo]. This was done 
because the published sequences were obtained 
from molecular cloning experiments with the at- 
tendant risk that a minor component of the virus 
population may have been selected (Rowlands et 
al., in preparation). The nucleotide sequences ob- 
1!3&A* 
Fig.1. Amino acid sequence of the C-terminal region of 
FMDV strains A10 (61) and Al2 (119). Sequences were 
derived by a primer extension method. Amino acids 
141-160 (underlined) indicate the region for which 
peptides were synthesised. The additional amino acid at 
position 212 is indicated. *See footnote on title page. 
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tamed are shown in fig.1. The sequence of A10 
agrees exactly with that obtained by molecular 
cloning methods, while that of Al2 differs only in 
the presence of an additions Ieucine residue at 
position 212. Nucleotide sequence data now 
available for 6 of the 7 serotypes (Clarke et al., in 
preparation) [5-7,11,12] show that the presence of 
Leu-Leu or Thr-Leu at positions 212-213 is 
universal. We therefore assume the absence of the 
leucine at 212 in the cloned Al2 [6] may be an 
artefact of cloning or sequencing. Comparative se- 
quence data between subtypes of serotype A 
[5,6,11,12] show a good degree of conservation 
between amino acids 200-213, whereas region 
141-160 shows ~~iderable variability. It seems 
logical therefore that subtype determinants may lie 
in the latter region. 
Table 1 
Cross-neutralization of viruses from subtypes A10 and 
Al2 with antivirion and antipeptide sera 
Log10 virus 
neutralized by 
0.015 ml serum 
Serum 
A10 antivirion - 
single inoculation 
into guinea pigs 
Diiution Al0 Al2 
l/l 4.5 1.9 
l/IO 3.8 1.3 
l/100 2.5 0.9 
l/l000 1.5 0.9 
A10 antipeptide - 
single inoculation 
into guinea pigs 
A10 antipeptide 7 
3 inoculations 
into rabbits 
l/4 2.7 0.5 
l/l 4.0 0.5 
Al2 antivirion - 
single inoculation 
into guinea pigs 
Al2 antipeptide - 
single inoculation 
into guinea pigs 
l/l 1.5 5.3 
l/IO 0.5 4.1 
l/100 0.7 3.5 
l/1000 nil 2.7 
l/l 0.5 2.5 
Al2 antipeptide - 
3 inoculations 
into rabbits 
l/l 2.5 >4.9 
Synthetic peptides corresponding to region 
141-M were therefore synthesised and the an- 
tibodies they elicited were used in serum neutrahsa- 
tion tests. The results of these tests show that the 
antisera produced by injection of inactivated virus 
particles or the 141-M peptides neutralised 
homologous viruses well but had o&y low activity 
against the heterologous viruses (table 1). This 
shows that the synthetic peptides mimic the anti- 
genie characteristics of the intact virus. The level 
of neutralising activity in the sera of the animals 
which had received the peptide was much lower 
than that in the antivirus particle sera [8,9]. This 
may be due to other components in the virus ar- 
chitecture holding the major ~tigenic site in a con- 
formation which the peptides do not accurately at- 
tain. Alternatively, the level of neutralising activity 
elicited by the coupled peptides may be a reflection 
of their presentation as antigens to the immune 
system. However, it is clear from these results that 
sequence 141-160 must contain sufficient infor- 
mation to contribute to subtype specificity. 
The interpretation of these results at the 
molecular level relies on predictive methods. It is 
highly unlikely that the side chains of all the 
residues in the antigenic site are sufficiently expos- 
ed to participate in the antibody recog~tion site 
and those that are buried in the hydrophobic ore 
of the protein cannot be antigenic determinants. It 
is possible to predict the presence or absence of 
specific amino acids in the protein core [14]. By 
combining such predictions with secondary struc- 
ture predictions [15] it is possible to construct 
three-dimensional structural models of the an- 
tigenic site (fig.2). Both peptides are predicted to 
be partly helical, the helix of A10 (Ser 150-lieu 
159) being slightly longer than that of Al2 (Pro 
153-Leu 159). The helices are disrupted by the 
presence of Gly 149 in A10 and Pro 153 in A12, 
while the deletion of Arg 145 in A10 causes a shift 
in the spatial arrangement of the amino acids at the 
N-terminus. In the intact virus the substitution of 
Leu for Phe at148 is unlikely to have any great in- 
fluence on the folding of the polypeptide chain, 
since both amino acids are predicted to be in core 
and to have a similar distribution of dihedral 
angles. The same argument applies to the Ile for 
Leu substitution at 15 1, leaving the main distinc- 
tion between A10 and Al2 as the relative lengths of 
the helices and their effect on the spatial position 
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of the groups in the N-terminal ~#on, and the 
substitution of Thr (A10) for Arg (AU) at position 
157. Work is now in progress using chimaeric pep- 
tidee from these two subtypes to determine which 
of these features is involved in subtype specificity. 
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